publication . Article . Other literature type . 2014

Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens

Yulia Ivanova; William E. Gillanders; Gordon J. Freeman; Alan J. Korman; Willem Jan Krebber; Takuro Noguchi; Ton N. M. Schumacher; Matthew D. Vesely; Ruedi Aebersold; Heiko Schuster; ...
Open Access English
  • Published: 26 Nov 2014
  • Country: United States
Abstract
The immune system plays key roles in determining the fate of developing cancers by not only functioning as a tumour promoter facilitating cellular transformation, promoting tumour growth and sculpting tumour cell immunogenicity1–6, but also as an extrinsic tumour suppressor that either destroys developing tumours or restrains their expansion1,2,7. Yet clinically apparent cancers still arise in immunocompetent individuals in part as a consequence of cancer induced immunosuppression. In many individuals, immunosuppression is mediated by Cytotoxic T-Lymphocyte Associated Antigen-4 (CTLA-4) and Programmed Death-1 (PD-1), two immunomodulatory receptors expressed on T...
Subjects
free text keywords: Multidisciplinary, Article, Cell cycle checkpoint, Immunology, Antigen, Checkpoint Blockade Immunotherapy, Immune system, Cancer immunotherapy, medicine.medical_treatment, medicine, Cytotoxic T cell, Biology, Immunotherapy, Blockade
Funded by
NIH| MOLECULAR REGULATION OF MACROPHAGE CYTOCIDAL ACTIVITY
Project
  • Funder: National Institutes of Health (NIH)
  • Project Code: 5R37CA043059-12
  • Funding stream: NATIONAL CANCER INSTITUTE
,
NIH| DF/HCC Kidney Cancer SPORE
Project
  • Funder: National Institutes of Health (NIH)
  • Project Code: 2P50CA101942-11A1
  • Funding stream: NATIONAL CANCER INSTITUTE
,
NIH| Role of Tim Family Genes in Asthma and Allergic Diseases
Project
  • Funder: National Institutes of Health (NIH)
  • Project Code: 5P01AI054456-05
  • Funding stream: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
,
NIH| Translational Insights into Estrogen Receptor alpha-Positive Luminal Breast Cance
Project
  • Funder: National Institutes of Health (NIH)
  • Project Code: 5U01CA141541-02
  • Funding stream: NATIONAL CANCER INSTITUTE
46 references, page 1 of 4

Shankaran, V. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature. 2001; 410: 1107-1111 [OpenAIRE] [PubMed] [DOI]

Dunn, GP, Bruce, AT, Ikeda, H, Old, LJ, Schreiber, RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nature immunology. 2002; 3: 991-998 [OpenAIRE] [PubMed] [DOI]

Mantovani, A, Allavena, P, Sica, A, Balkwill, F. Cancer-related inflammation. Nature. 2008; 454: 436-444 [OpenAIRE] [PubMed] [DOI]

Grivennikov, SI, Greten, FR, Karin, M. Immunity, inflammation, and cancer. Cell. 2010; 140: 883-899 [OpenAIRE] [PubMed] [DOI]

Trinchieri, G. Cancer and inflammation: an old intuition with rapidly evolving new concepts. Annual review of immunology. 2012; 30: 677-706 [OpenAIRE] [DOI]

Coussens, LM, Zitvogel, L, Palucka, AK. Neutralizing tumor-promoting chronic inflammation: a magic bullet?. Science. 2013; 339: 286-291 [OpenAIRE] [PubMed] [DOI]

Koebel, CM. Adaptive immunity maintains occult cancer in an equilibrium state. Nature. 2007; 450: 903-907 [OpenAIRE] [PubMed] [DOI]

Quezada, SA, Peggs, KS, Simpson, TR, Allison, JP. Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication. Immunological reviews. 2011; 241: 104-118 [OpenAIRE] [PubMed] [DOI]

Pardoll, DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012; 12: 252-264 [OpenAIRE] [PubMed] [DOI]

Wolchok, JD. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013; 369: 122-133 [OpenAIRE] [PubMed] [DOI]

Hamid, O. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013; 369: 134-144 [OpenAIRE] [PubMed] [DOI]

Topalian, SL. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. The New England journal of medicine. 2012; 366: 2443-2454 [OpenAIRE] [PubMed] [DOI]

Hodi, FS. Improved survival with ipilimumab in patients with metastatic melanoma. The New England journal of medicine. ; 363: 711-723 [OpenAIRE] [PubMed]

Matsushita, H. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature. ; 482: 400-404 [OpenAIRE] [PubMed]

Paul, S. HLA class I alleles are associated with peptide-binding repertoires of different size, affinity, and immunogenicity. Journal of immunology. 2013; 191: 5831-5839 [OpenAIRE] [DOI]

46 references, page 1 of 4
Abstract
The immune system plays key roles in determining the fate of developing cancers by not only functioning as a tumour promoter facilitating cellular transformation, promoting tumour growth and sculpting tumour cell immunogenicity1–6, but also as an extrinsic tumour suppressor that either destroys developing tumours or restrains their expansion1,2,7. Yet clinically apparent cancers still arise in immunocompetent individuals in part as a consequence of cancer induced immunosuppression. In many individuals, immunosuppression is mediated by Cytotoxic T-Lymphocyte Associated Antigen-4 (CTLA-4) and Programmed Death-1 (PD-1), two immunomodulatory receptors expressed on T...
Subjects
free text keywords: Multidisciplinary, Article, Cell cycle checkpoint, Immunology, Antigen, Checkpoint Blockade Immunotherapy, Immune system, Cancer immunotherapy, medicine.medical_treatment, medicine, Cytotoxic T cell, Biology, Immunotherapy, Blockade
Funded by
NIH| MOLECULAR REGULATION OF MACROPHAGE CYTOCIDAL ACTIVITY
Project
  • Funder: National Institutes of Health (NIH)
  • Project Code: 5R37CA043059-12
  • Funding stream: NATIONAL CANCER INSTITUTE
,
NIH| DF/HCC Kidney Cancer SPORE
Project
  • Funder: National Institutes of Health (NIH)
  • Project Code: 2P50CA101942-11A1
  • Funding stream: NATIONAL CANCER INSTITUTE
,
NIH| Role of Tim Family Genes in Asthma and Allergic Diseases
Project
  • Funder: National Institutes of Health (NIH)
  • Project Code: 5P01AI054456-05
  • Funding stream: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
,
NIH| Translational Insights into Estrogen Receptor alpha-Positive Luminal Breast Cance
Project
  • Funder: National Institutes of Health (NIH)
  • Project Code: 5U01CA141541-02
  • Funding stream: NATIONAL CANCER INSTITUTE
46 references, page 1 of 4

Shankaran, V. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature. 2001; 410: 1107-1111 [OpenAIRE] [PubMed] [DOI]

Dunn, GP, Bruce, AT, Ikeda, H, Old, LJ, Schreiber, RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nature immunology. 2002; 3: 991-998 [OpenAIRE] [PubMed] [DOI]

Mantovani, A, Allavena, P, Sica, A, Balkwill, F. Cancer-related inflammation. Nature. 2008; 454: 436-444 [OpenAIRE] [PubMed] [DOI]

Grivennikov, SI, Greten, FR, Karin, M. Immunity, inflammation, and cancer. Cell. 2010; 140: 883-899 [OpenAIRE] [PubMed] [DOI]

Trinchieri, G. Cancer and inflammation: an old intuition with rapidly evolving new concepts. Annual review of immunology. 2012; 30: 677-706 [OpenAIRE] [DOI]

Coussens, LM, Zitvogel, L, Palucka, AK. Neutralizing tumor-promoting chronic inflammation: a magic bullet?. Science. 2013; 339: 286-291 [OpenAIRE] [PubMed] [DOI]

Koebel, CM. Adaptive immunity maintains occult cancer in an equilibrium state. Nature. 2007; 450: 903-907 [OpenAIRE] [PubMed] [DOI]

Quezada, SA, Peggs, KS, Simpson, TR, Allison, JP. Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication. Immunological reviews. 2011; 241: 104-118 [OpenAIRE] [PubMed] [DOI]

Pardoll, DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012; 12: 252-264 [OpenAIRE] [PubMed] [DOI]

Wolchok, JD. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013; 369: 122-133 [OpenAIRE] [PubMed] [DOI]

Hamid, O. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013; 369: 134-144 [OpenAIRE] [PubMed] [DOI]

Topalian, SL. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. The New England journal of medicine. 2012; 366: 2443-2454 [OpenAIRE] [PubMed] [DOI]

Hodi, FS. Improved survival with ipilimumab in patients with metastatic melanoma. The New England journal of medicine. ; 363: 711-723 [OpenAIRE] [PubMed]

Matsushita, H. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature. ; 482: 400-404 [OpenAIRE] [PubMed]

Paul, S. HLA class I alleles are associated with peptide-binding repertoires of different size, affinity, and immunogenicity. Journal of immunology. 2013; 191: 5831-5839 [OpenAIRE] [DOI]

46 references, page 1 of 4
Any information missing or wrong?Report an Issue